Simian (gorilla) adenovirus or adenoviral vectors and methods of use
View Patent ↗The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
1. An adenovirus or adenoviral vector comprising a non-native nucleic acid sequence and a nucleic acid sequence that is at least 96.52% identical to SEQ ID NO: 9.
2. The adenovirus or adenoviral vector of claim 1 , which further comprises one or more of the nucleic acid sequences selected from the group consisting of:
(a) a nucleic acid sequence that is at least 98.4% identical to SEQ ID NO: 6,
(b) a nucleic acid sequence that is at least 99.01% identical to SEQ ID NO: 7,
(c) a nucleic acid sequence that is at least 97.08% identical to SEQ ID NO: 8, and
(d) a nucleic acid sequence that is at least 98.49% identical to SEQ ID NO: 10.
3. The adenovirus or adenoviral vector of claim 2 , which comprises a nucleic acid sequence that is at least 98.4% identical to SEQ ID NO: 6.
4. The adenovirus or adenoviral vector of claim 3 , which comprises the nucleic acid sequence of SEQ ID NO: 6.
5. The adenovirus or adenoviral vector of claim 2 , which comprises a nucleic acid sequence that is at least 99.01% identical to SEQ ID NO: 7.
6. The adenovirus or adenoviral vector of claim 5 , which comprises the nucleic acid sequence of SEQ ID NO: 7.
7. The adenovirus or adenoviral vector of claim 2 , which comprises a nucleic acid sequence that is at least 97.08% identical to SEQ ID NO: 8.
8. The adenovirus or adenoviral vector of claim 7 , which comprises the nucleic acid sequence of SEQ ID NO: 8.
9. The adenovirus or adenoviral vector of claim 1 , which comprises the nucleic acid sequence of SEQ ID NO: 9.
10. The adenovirus or adenoviral vector of claim 2 , which comprises a nucleic acid sequence that is at least 98.49% identical to SEQ ID NO: 10.
11. The adenovirus or adenoviral vector of claim 10 , which comprises the nucleic acid sequence of SEQ ID NO: 10.
12. An adenovirus or adenoviral vector comprising a non-native nucleic acid sequence and a nucleic acid sequence comprising at least 606 contiguous nucleotides of SEQ ID NO: 9.
13. The adenovirus or adenoviral vector of claim 12 , which further comprises one or more of the nucleic acid sequences selected from the group consisting of:
(a) a nucleic acid sequence comprising at least 121 contiguous nucleotides of SEQ ID NO: 6,
(b) a nucleic acid sequence comprising at least 462 contiguous nucleotides of SEQ ID NO: 7,
(c) a nucleic acid sequence comprising at least 234 contiguous nucleotides of SEQ ID NO: 8, and
(d) a nucleic acid sequence comprising at least 188 contiguous nucleotides of SEQ ID NO: 10.
14. The adenovirus or adenoviral vector of claim 13 , which comprises a nucleic acid sequence comprising at least 121 contiguous nucleotides of SEQ ID NO: 6.
15. The adenovirus or adenoviral vector of claim 14 , which comprises the nucleic acid sequence of SEQ ID NO: 6.
16. The adenovirus or adenoviral vector of claim 13 , which comprises a nucleic acid sequence comprising at least 462 contiguous nucleotides of SEQ ID NO: 7.
17. The adenovirus or adenoviral vector of claim 16 , which comprises the nucleic acid sequence of SEQ ID NO: 7.
18. The adenovirus or adenoviral vector of claim 13 , which comprises a nucleic acid sequence comprising at least 234 contiguous nucleotides of SEQ ID NO: 8.
19. The adenovirus or adenoviral vector of claim 18 , which comprises the nucleic acid sequence of SEQ ID NO: 8.
20. The adenovirus or adenoviral vector of claim 12 , which comprises the nucleic acid sequence of SEQ ID NO: 9.
21. The adenovirus or adenoviral vector of claim 13 , which comprises a nucleic acid sequence comprising at least 188 contiguous nucleotides of SEQ ID NO: 10.
22. The adenovirus or adenoviral vector of claim 21 , which comprises the nucleic acid sequence of SEQ ID NO: 10.
23. The adenovirus or adenoviral vector of claim 12 , wherein the adenovirus or adenoviral vector requires complementation of a deficiency in one or more early regions of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.
24. The adenovirus or adenoviral vector of claim 12 , wherein the non-native nucleic acid sequence is a transgene.
25. A composition comprising the adenovirus or adenoviral vector of claim 1 and a pharmaceutically acceptable carrier.
26. The adenovirus or adenoviral vector of claim 1 , wherein the adenovirus or adenoviral vector requires complementation of a deficiency in one or more early regions of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.
27. The adenovirus or adenoviral vector of claim 1 , wherein the non-native nucleic acid sequence is a transgene.
28. A composition comprising the adenovirus or adenoviral vector of claim 1 and a pharmaceutically acceptable carrier.
29. The adenovirus or adenoviral vector of claim 1 , wherein the non-native nucleic acid sequence is a transgene or a nucleic acid sequence naturally found in an adenovirus but located at a non-native position within the adenoviral genome.
30. The adenovirus or adenoviral vector of claim 12 , wherein the non-native nucleic acid sequence is naturally found in an adenovirus but located at a non-native position within the adenoviral genome.